What IMMUNE DESIGN CORP.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Column Group L P | 10% owner | Apr 02 | Tender Offer · U | −6,642,942 | $5.85 | −$38.9M | 0 |
| Paya Carlos V | President and CEO | Apr 02 | Disposition to Issuer · D | −35,576 | $5.85 | −$208K | 0 |
| Berger Franklin M | Director | Apr 02 | Disposition to Issuer · D | −75,000 | $5.85 | −$439K | 0 |
| Baltimore David | Director | Apr 02 | Disposition to Issuer · D | −78,287 | $5.85 | −$458K | 0 |
| Coleman Lewis W | Director | Apr 02 | Disposition to Issuer · D | −3,000 | $5.85 | −$17.6K | 0 |
| Coleman Lewis W | Director | Apr 02 | Disposition to Issuer · D | −175,000 | $5.85 | −$1.02M | 0 |
| Yurasov Sergey | Sr. VP, Clinic. Devel. & CMO | Apr 02 | Disposition to Issuer · D | −6,136 | $5.85 | −$35.9K | 0 |
| Gombotz Wayne | Chief Development Officer | Apr 02 | Disposition to Issuer · D | −37,068 | — | — | 0 |
| ter Meulen Jan Henrik | Chief Scientific Officer | Apr 02 | Disposition to Issuer · D | −14,620 | $5.85 | −$85.5K | 0 |
| Brady Stephen R | EVP, Strategy & Finance | Apr 02 | Disposition to Issuer · D | −17,063 | $5.85 | −$99.8K | 0 |
| Paya Carlos V | President and CEO | Jan 07 | Open-market sale · S | −13,014 | $1.58 | −$20.6K | 156,576 |
| Brady Stephen R | EVP, Strategy & Finance | Jan 07 | Open-market sale · S | −5,516 | $1.58 | −$8.72K | 96,599 |
| Yurasov Sergey | Sr. VP, Clinic. Devel. & CMO | Jan 07 | Open-market sale · S | −3,522 | $1.57 | −$5.54K | 78,756 |
| ter Meulen Jan Henrik | Chief Scientific Officer | Jan 07 | Open-market sale · S | −3,414 | $1.59 | −$5.41K | 83,982 |
| Paya Carlos V | President and CEO | Jan 03 | Grant / award · A | +63,000 | — | — | 169,590 |
| Brady Stephen R | EVP, Strategy & Finance | Jan 03 | Grant / award · A | +25,000 | — | — | 102,115 |
| Yurasov Sergey | Sr. VP, Clinic. Devel. & CMO | Jan 03 | Grant / award · A | +25,000 | — | — | 82,278 |
| ter Meulen Jan Henrik | Chief Scientific Officer | Jan 03 | Grant / award · A | +25,000 | — | — | 87,396 |
| Bvf Partners L P/IL | 10% owner | Dec 04 | Open-market sale · S | −89,948 | $1.83 | −$165K | 370,391 |
| Bvf Partners L P/IL | 10% owner | Dec 04 | Open-market sale · S | −382,017 | $1.83 | −$700K | 1,942,764 |
Loading...
